

Safety, tolerability, pharmacokinetics, and pharmacody  
administration of multiple doses of cagrilintide with ser  
management: a randomised, controlled, phase 1b trial

Lancet, The

397, 1736-1748

DOI: [10.1016/s0140-6736\(21\)00845-x](https://doi.org/10.1016/s0140-6736(21)00845-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cagrilintide plus semaglutide for obesity management. <i>Lancet, The</i> , 2021, 397, 1687-1689.	13.7	20
2	Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 2807-2827.	2.4	32
3	Pharmacotherapeutic Options for Weight Regain After Bariatric Surgery. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 524-541.	0.8	5
4	Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 231-243.	2.4	51
5	Pharmacological characterisation of mouse calcitonin and calcitonin receptor-like receptors reveals differences compared with human receptors. <i>British Journal of Pharmacology</i> , 2022, 179, 416-434.	5.4	16
6	Development of Cagrilintide, a Long-Acting Amylin Analogue. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11183-11194.	6.4	41
7	Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?. <i>Cardiovascular Research</i> , 2021, 117, e120-e122.	3.8	3
8	Future perspectives in diabetes treatment: Semaglutide, a glucagon-like peptide-1 receptor agonist (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1167.	1.8	7
9	New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review. <i>Pharmaceuticals</i> , 2021, 14, 869.	3.8	11
11	Effects of Combined Oxytocin and Beta-3 Receptor Agonist (CL 316243) Treatment on Body Weight and Adiposity in Male Diet-Induced Obese Rats. <i>Frontiers in Physiology</i> , 2021, 12, 725912.	2.8	10
13	Amylin, bariatric surgery and type 2 diabetes mellitus. <i>Journal of the Chinese Medical Association</i> , 2021, Publish Ahead of Print, 983-984.	1.4	5
14	Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. <i>Lancet, The</i> , 2022, 399, 394-405.	13.7	215
15	Tirzepatide: a new low for bodyweight and blood glucose. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 646-648.	11.4	10
16	Islet amyloid toxicity: From genesis to counteracting mechanisms. <i>Journal of Cellular Physiology</i> , 2022, 237, 1119-1142.	4.1	2
17	GLP-1 physiology informs the pharmacotherapy of obesity. <i>Molecular Metabolism</i> , 2022, 57, 101351.	6.5	119
18	Oxytocin as an Anti-obesity Treatment. <i>Frontiers in Neuroscience</i> , 2021, 15, 743546.	2.8	12
19	Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. <i>Endocrine Reviews</i> , 2022, 43, 507-557.	20.1	39
20	High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management. <i>Annals of Pharmacotherapy</i> , 2022, 56, 941-950.	1.9	7

#	ARTICLE	IF	CITATIONS
21	Amyloidogenicity of peptides targeting diabetes and obesity. <i>Colloids and Surfaces B: Biointerfaces</i> , 2022, 209, 112157.	5.0	5
22	Peptides in the regulation of glucagon secretion. <i>Peptides</i> , 2022, 148, 170683.	2.4	16
24	Is Obesity or Adiposity-Based Chronic Disease Curable: The Set Point Theory, the Environment, and Second-Generation Medications. <i>Endocrine Practice</i> , 2022, 28, 214-222.	2.1	19
25	Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. <i>Lancet, The</i> , 2021, 398, 1965-1973.	13.7	43
26	Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. <i>Lancet, The</i> , 2021, 398, 2160-2172.	13.7	74
27	Anti-obesity drug discovery: advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 201-223.	46.4	357
28	Long-acting amylin analogue for weight reduction. <i>Lancet, The</i> , 2021, 398, 2132-2134.	13.7	6
29	Bariatric/Metabolic Surgery. <i>Handbook of Experimental Pharmacology</i> , 2021, , 371-386.	1.8	3
30	Drugs for Treating Obesity. <i>Handbook of Experimental Pharmacology</i> , 2021, , 387-414.	1.8	12
31	Hypophagia induced by salmon calcitonin, but not by amylin, is partially driven by malaise and is mediated by CGRP neurons. <i>Molecular Metabolism</i> , 2022, 58, 101444.	6.5	4
32	Is polypharmacy the future for pharmacological management of obesity?. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022, 23, 100322.	1.4	5
33	Novel Drugs for Diabetes Therapy. <i>Handbook of Experimental Pharmacology</i> , 2022, , 1.	1.8	0
34	Long-acting amylin analogues for the management of obesity. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022, 29, 183-190.	2.3	15
35	Oxytocin as a potential pharmacological tool to combat obesity. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13106.	2.6	7
36	Growth differentiation factor 15 (<scp>GDF15</scp>) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1010-1020.	4.4	14
37	New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1339-e1347.	3.6	33
38	Turning the clock forward: New pharmacological and not pharmacological targets for the treatment of obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	2.6	3
39	A structural basis for amylin receptor phenotype. <i>Science</i> , 2022, 375, eabm9609.	12.6	28

#	ARTICLE	IF	CITATIONS
40	What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 359-375.	2.0	22
41	Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. <i>Obesity</i> , 2022, 30, 841-857.	3.0	25
42	THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin â€œ physiology and pharmacology. <i>European Journal of Endocrinology</i> , 2022, 186, R93-R111.	3.7	4
43	Pharmacotherapeutic options in pediatric obesity: an urgent call for further research. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , 1-4.	1.8	1
44	Managing weight and glycaemic targets in people with type 2 diabetesâ€™How far have we come?. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00330.	2.4	9
45	Obesityâ€™related glomerulopathy: Current approaches and future perspectives. <i>Obesity Reviews</i> , 2022, 23, e13450.	6.5	26
46	GLP-1 â€™ Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy. <i>Current Opinion in Pharmacology</i> , 2022, 63, 102189.	3.5	10
47	Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists. <i>European Journal of Medicinal Chemistry</i> , 2022, 236, 114330.	5.5	2
48	Creating the amylin story. <i>Appetite</i> , 2022, 172, 105965.	3.7	21
49	Amylin as a Future Obesity Treatment. <i>Journal of Obesity and Metabolic Syndrome</i> , 2021, 30, 320-325.	3.6	15
50	Targeting the Enteroendocrine System for Treatment of Obesity. <i>Handbook of Experimental Pharmacology</i> , 2022, , 1.	1.8	0
51	Mediators of Amylin Action in Metabolic Control. <i>Journal of Clinical Medicine</i> , 2022, 11, 2207.	2.4	9
52	Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. <i>Expert Review of Clinical Pharmacology</i> , 2022, , 1-17.	3.1	5
54	Linking hIAPP misfolding and aggregation with type 2 diabetes mellitus: a structural perspective. <i>Bioscience Reports</i> , 2022, 42, .	2.4	2
55	Slow and steady wins the race: 25 years developing the GLP-1 receptor as an effective target for weight loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	4
56	SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 424-442.	7.1	23
57	Breakthroughs in therapies for NASH and remaining challenges. <i>Journal of Hepatology</i> , 2022, 76, 1263-1278.	3.7	66
59	Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. <i>Pharmaceutical Research</i> , 2022, 39, 1233-1248.	3.5	31

#	ARTICLE	IF	CITATIONS
60	GLP-1 analogues in clinical management of obesity. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022, , 100360.	1.4	3
61	Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors. <i>Biochemical Pharmacology</i> , 2022, 202, 115115.	4.4	5
63	Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211080.	2.5	10
64	Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?. , 2022, 18, 35.		5
65	<scp>Glucagonâ€like peptide</scp>â€1, glucoseâ€dependent insulinotropic polypeptide, and glucagon receptor polyâ€agonists: a new era in obesity pharmacotherapy. <i>Obesity</i> , 2022, 30, 1718-1721.	3.0	4
66	The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211124.	3.2	9
67	Pharmacologic treatment of obesity. <i>Journal of the Korean Medical Association</i> , 2022, 65, 408-416.	0.3	0
68	Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. <i>Endocrine Reviews</i> , 2023, 44, 14-32.	20.1	32
69	Derivatization with fatty acids in peptide and protein drug discovery. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 59-80.	46.4	19
71	Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer. <i>Cancer Discovery</i> , 2022, 12, 2258-2279.	9.4	18
72	Medical and Surgical Treatment of Obesity. <i>Medical Clinics of North America</i> , 2022, 106, 837-852.	2.5	3
73	Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review. <i>Clinical Pharmacology: Advances and Applications</i> , 0, Volume 14, 61-67.	1.2	3
74	Are Current Guidelines Perpetuating Weight Stigma? A Weight-Skeptical Approach to the Care of Patients with Obesity. <i>Journal of General Internal Medicine</i> , 0, , .	2.6	1
75	The potential of glucagon-like peptide-1 receptor agonists in heart failure. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	3
76	A new era in gut hormone-based pharmacotherapy for people with obesity. <i>Proceedings of the Nutrition Society</i> , 2022, 81, 217-226.	1.0	5
77	The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist Therapy. <i>Biomedicines</i> , 2022, 10, 2365.	3.2	4
78	New Horizons: Emerging Antidiabetic Medications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e4333-e4340.	3.6	6
79	Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. <i>Cardiovascular Diabetology</i> , 2022, 21, .	6.8	79

#	ARTICLE	IF	CITATIONS
81	Semaglutide for the treatment of overweight and obesity: A review. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 18-35.	4.4	26
82	Pharmacotherapy of type 2 diabetes: An update and future directions. <i>Metabolism: Clinical and Experimental</i> , 2022, 137, 155332.	3.4	35
83	Does receptor balance matter? â€œ Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113842.	5.6	6
84	Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin. <i>European Journal of Pharmacology</i> , 2023, 938, 175397.	3.5	3
85	New therapies for obesity. <i>Cardiovascular Research</i> , 2024, 119, 2825-2842.	3.8	16
86	Co-agonist therapeutics come of age for obesity. <i>Nature Reviews Endocrinology</i> , 2023, 19, 66-67.	9.6	5
88	An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.2	5
89	An update on peptide-based therapies for type 2 diabetes and obesity. <i>Peptides</i> , 2023, 161, 170939.	2.4	34
90	New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. <i>Annual Review of Medicine</i> , 2023, 74, 125-139.	12.2	20
91	The Long Way of Oxytocin from the Uterus to the Heart in 70 Years from Its Discovery. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2556.	4.1	6
92	The fundamental role of obesity management in cardiometabolic risk reduction: nonpharmacological, pharmacological, and surgical approaches. , 2023, , 273-309.		0
93	Current and emerging medications for the management of obesity in adults. <i>Medical Journal of Australia</i> , 2023, 218, 276-283.	1.7	5
94	Glucagonâ€like peptideâ€1 receptor agonists to expand the healthy lifespan: Current and future potentials. <i>Aging Cell</i> , 2023, 22, .	6.7	1
95	Targeting G protein-coupled receptors to regulate energy homeostasis. <i>Journal of Molecular Endocrinology</i> , 2023, , .	2.5	0
96	Hormonal Gutâ€Brain Signaling for the Treatment of Obesity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3384.	4.1	8
97	Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. <i>Journal of Obesity and Metabolic Syndrome</i> , 2023, 32, 25-45.	3.6	14
98	Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes. <i>Cardiovascular Endocrinology and Metabolism</i> , 2023, 12, e0279.	1.1	3
99	An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 111-130.	2.4	3

#	ARTICLE	IF	CITATIONS
100	Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. <i>Cardiology in Review</i> , 2024, 32, 83-90.	1.4	2
102	Diabesity and the Kidney. <i>Frontiers in Clinical Drug Research Diabetes and Obesity</i> , 2023, , 168-207.	0.1	0
103	Novel Anti-Obesity Pharmacotherapies. , 0, , .		0
104	Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. <i>Nature Reviews Cardiology</i> , 2023, 20, 463-474.	13.7	46
105	Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options. <i>Molecules</i> , 2023, 28, 3094.	3.8	10
106	The Physiological Regulation of Body Fat Mass. <i>Gastroenterology Clinics of North America</i> , 2023, , .	2.2	0
107	Bariatric“metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. <i>Lancet, The</i> , 2023, 401, 1786-1797.	13.7	48
108	Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications. <i>Current Obesity Reports</i> , 2023, 12, 127-146.	8.4	5
109	Type“2 Diabetes, Pancreatic Amylin, and Neuronal Metabolic Remodeling in Alzheimer's Disease. <i>Molecular Nutrition and Food Research</i> , 0, , .	3.3	0
110	Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities. <i>Journal of the National Cancer Institute Monographs</i> , 2023, 2023, 68-76.	2.1	0
112	Pharmacotherapy for chronic obesity management: a look into the future. <i>Internal and Emergency Medicine</i> , 0, , .	2.0	0
113	Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss. <i>Biomedicine and Pharmacotherapy</i> , 2023, 164, 114969.	5.6	3
114	Obesity: medical management. <i>Medicine</i> , 2023, 51, 509-514.	0.4	0
115	A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy“ A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9760.	4.1	4
116	Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss. <i>European Journal of Pharmacology</i> , 2023, 954, 175837.	3.5	2
117	Current and future pharmacotherapies for obesity in children and adolescents. <i>Nature Reviews Endocrinology</i> , 2023, 19, 534-541.	9.6	4
118	New IFSO/ASMBS Indications for Metabolic and Bariatric Surgery? Yes, After Failure of Best Nonsurgical Therapy. <i>Obesity Surgery</i> , 0, , .	2.1	1
119	Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes. <i>BIO Web of Conferences</i> , 2023, 61, 01006.	0.2	0

#	ARTICLE	IF	CITATIONS
120	Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. <i>Journal of Obesity and Metabolic Syndrome</i> , 2023, 32, 106-120.	3.6	6
121	CagriSema and the link between obesity and type 2 diabetes. <i>Lancet, The</i> , 2023, 402, 671-673.	13.7	1
122	Efficacy and safety of co-administered once-weekly cagrilintide 2Â·4 mg with once-weekly semaglutide 2Â·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. <i>Lancet, The</i> , 2023, 402, 720-730.	13.7	36
123	Diagnostic challenge: A pediatric patient with severe obesity and complications of imminent death. , 2023, 7, 100077.		0
124	Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 989-1000.	1.8	3
125	Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 307-319.	2.4	5
126	GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. <i>Cell Reports</i> , 2023, 42, 112466.	6.4	1
128	Tripleâ€‘Hormone-Receptor Agonist Retatrutide for Obesity â€‘ A Phase 2 Trial. <i>New England Journal of Medicine</i> , 2023, 389, 514-526.	27.0	143
129	Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection. <i>Canadian Journal of Cardiology</i> , 2023, 39, 1816-1838.	1.7	2
131	The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2023, 66, 1846-1858.	6.3	6
132	Amylin Modulates a Ventral Tegmental Areaâ€‘toâ€‘Medial Prefrontal Cortex Circuit to Suppress Food Intake and Impulsive Food-Directed Behavior. <i>Biological Psychiatry</i> , 2023, , .	1.3	0
133	Future therapies for obesity. <i>Clinical Medicine</i> , 2023, 23, 337-346.	1.9	4
134	Structural insight into selectivity of amylin and calcitonin receptor agonists. <i>Nature Chemical Biology</i> , 2024, 20, 162-169.	8.0	2
135	GIPR/GLP-1R dual agonist therapies for diabetes and weight lossâ€‘chemistry, physiology, and clinical applications. <i>Cell Metabolism</i> , 2023, 35, 1519-1529.	16.2	18
136	Obesity-Related Kidney Disease: Current Understanding and Future Perspectives. <i>Biomedicines</i> , 2023, 11, 2498.	3.2	3
137	Universal Prior Authorization Template for glucagon like peptide-1 based anti-obesity medications: An Obesity Medicine Association proposal. , 2023, 8, 100079.		1
138	Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?. <i>Sleep</i> , 2023, 46, .	1.1	2
139	Gut Hormones and Metabolic Syndrome. , 2023, , 1-16.		0



#	ARTICLE	IF	CITATIONS
141	Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin. <i>Diabetes Therapy</i> , 2023, 14, 1997-2014.	2.5	1
142	An updated patent review of GLP-1 receptor agonists (2020-present). <i>Expert Opinion on Therapeutic Patents</i> , 2023, 33, 597-612.	5.0	0
143	Anti-obesity pharmacotherapy in adults with chronic kidney disease. <i>Kidney International</i> , 2023, , .	5.2	1
144	The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. <i>Current Obesity Reports</i> , 2023, 12, 453-473.	8.4	5
145	Newer pharmacological interventions directed at gut hormones for obesity. <i>British Journal of Pharmacology</i> , 0, , .	5.4	0
146	Seeking satiety: From signals to solutions. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	0
147	Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity. <i>Calcified Tissue International</i> , 2024, 114, 86-97.	3.1	1
148	G protein-coupled receptors and obesity. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
149	Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges. <i>Drugs</i> , 2024, 84, 127-148.	10.9	0
150	Weight Loss Interventions for Adults With Obesity-Related Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2024, 12, 840-847.	3.8	1
151	Pharmacotherapy for obesity: moving towards efficacy improvement. <i>Diabetology and Metabolic Syndrome</i> , 2024, 16, .	2.7	0
152	Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis. <i>Biomedicine and Pharmacotherapy</i> , 2024, 171, 116150.	5.6	0
153	Nonpharmacological, pharmacological, and surgical options for obesity-related cardiometabolic disorders. , 2023, , 339-369.		0
154	Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabetes. <i>International Journal of Molecular Sciences</i> , 2024, 25, 1517.	4.1	0
155	Gut Hormones and Metabolic Syndrome. , 2023, , 357-372.		0
156	What is the pipeline for future medications for obesity?. <i>International Journal of Obesity</i> , 0, , .	3.4	1
157	Obesity and the kidney: mechanistic links and therapeutic advances. <i>Nature Reviews Endocrinology</i> , 0, , .	9.6	0
158	The processing intermediate of human amylin, pro-amylin(1-48), has in vivo and in vitro bioactivity. <i>Biophysical Chemistry</i> , 2024, 308, 107201.	2.8	0

#	ARTICLE	IF	CITATIONS
159	Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus. International Journal of Peptide Research and Therapeutics, 2024, 30, .	1.9	0
160	Effectiveness and safety of drugs for obesity. BMJ, The, 0, , e072686.	6.0	0